1 Introduction
2 Materials and Methods
2.1 Patients
2.2 Management
2.3 Outcome
2.4 Cerebral physiological data – acquisition and analysis
2.5 Visualizations of PRx insults
2.6 Statistical analysis
2.7 Ethics
3 Results
3.1 Demography, admission variables, treatments, and clinical outcome
aSAH | TBI | p-value | |
---|---|---|---|
Patients, n (%) | 487 (54%) | 413 (46%) | NA |
Age, median (IQR) | 59 (51–67) | 52 (31–65) | < 0.001 |
Sex (male/female), n (%) | 160/327 (33/67%) | 324/89 (78/22%) | < 0.001 |
GCS M at admission, median (IQR) | 6 (5–6) | 5 (4–5) | < 0.001 |
Pupillary status (unreactive), n (%) | 28 (6%) | 79 (19%) | < 0.001 |
ICP-monitoring (intraparenchymal/EVD/both), n (%) | 9/444/34 (2/91/7%) | 237/80/96 (57/19/23%) | < 0.001 |
Thiopental, n (%) | 51 (10%) | 52 (13%) | 0.32 |
DC, n (%) | 51 (10%) | 45 (11%) | 0.84 |
GOS-E, median (IQR) | 3 (3–5) | 5 (3–7) | < 0.001 |
Favorable outcome, n (%) | 151 (31%) | 221 (54%) | < 0.001 |
Mortality, n (%) | 111 (23%) | 66 (16%) | 0.01 |
3.2 Cerebral physiology during the first 10 days after the acute brain injury
3.3 %GMT in certain PRx intervals in relation to demography, admission variables, and treatments
PRx interval | aSAH | TBI | ||||||
---|---|---|---|---|---|---|---|---|
Age | GCS M | ICP | CPP | Age | GCS M | ICP | CPP | |
-1.0 ≤ PRx ≤ -0.75 (%GMT) | -0.03 | -0.20c | 0.08 | -0.07 | -0.26c | 0.04 | 0.10a | -0.19c |
-0.75 < PRx ≤ -0.50 (%GMT) | -0.03 | -0.14b | 0.01 | 0.02 | -0.26c | 0.04 | -0.02 | -0.11a |
-0.50 < PRx ≤ -0.25 (%GMT) | -0.08 | -0.10a | -0.06 | 0.08 | -0.31c | 0.06 | -0.09 | -0.12a |
-0.25 < PRx ≤ 0.00 (%GMT) | -0.13b | -0.02 | -0.07 | 0.11a | -0.22c | 0.06 | -0.10a | -0.06 |
0.00 < PRx ≤ + 0.25 (%GMT) | -0.10a | 0.19c | -0.16c | 0.21c | 0.23c | 0.10a | -0.11a | 0.23c |
+ 0.25 < PRx ≤ + 0.50 (%GMT) | 0.07 | 0.29c | -0.25c | 0.25c | 0.35c | 0.06 | -0.05 | 0.28c |
+ 0.50 < PRx ≤ + 0.75 (%GMT) | 0.13b | 0.09a | -0.08 | 0.04 | 0.26c | -0.05 | 0.00 | 0.14b |
+ 0.75 < PRx ≤ + 1.0 (%GMT) | 0.16c | -0.19c | 0.15b | -0.37c | -0.08 | -0.20c | 0.07 | -0.22c |
3.4 Linear and quadratic fits for PRx versus GOS-E
3.5 %GMT in certain PRx intervals in relation to outcome
aSAH | TBI | |
---|---|---|
-1.0 ≤ PRx ≤ -0.75 (%GMT) | -0.17c | 0.13b |
-0.75 < PRx ≤ -0.50 (%GMT) | -0.03 | 0.18c |
-0.50 < PRx ≤ -0.25 (%GMT) | 0.11a | 0.22c |
-0.25 < PRx ≤ 0.00 (%GMT) | 0.20c | 0.21c |
0.00 < PRx ≤ + 0.25 (%GMT) | 0.35c | 0.00 |
+ 0.25 < PRx ≤ + 0.50 (%GMT) | 0.24c | -0.11a |
+ 0.50 < PRx ≤ + 0.75 (%GMT) | -0.07 | -0.18c |
+ 0.75 < PRx ≤ + 1.0 (%GMT) | -0.37c | -0.16b |
PRx interval [regression number] | aSAH (a) | TBI (b) | ||
---|---|---|---|---|
OR (95% CI) | p-value | OR (95% CI) | p-value | |
-1 ≤ PRx ≤ -0.75 (GMT) [1] | 0.57 (0.35–0.88) | 0.02 | 1.05 (0.86–1.29) | 0.64 |
-0.75 < PRx ≤ -0.50 (GMT) [2] | 0.92 (0.84–0.996) | 0.046 | 1.02 (0.97–1.08) | 0.48 |
-0.50 < PRx ≤ -0.25 (GMT) [3] | 0.99 (0.94–1.03) | 0.56 | 1.03 (0.99–1.06) | 0.24 |
-0.25 < PRx ≤ 0.00 (GMT) [4] | 1.00 (0.96–1.03) | 0.78 | 1.02 (0.99–1.07) | 0.21 |
0.00 < PRx ≤ + 0.25 (GMT) [5] | 1.09 (1.03–1.14) | 0.002 | 1.01 (0.97–1.06) | 0.48 |
+ 0.25 < PRx ≤ + 0.50 (GMT) [6] | 1.05 (1.01–1.09) | 0.02 | 1.00 (0.97–1.04) | 0.84 |
+ 0.50 < PRx ≤ + 0.75 (GMT) [7] | 0.99 (0.96–1.02) | 0.65 | 0.98 (0.94–1.02) | 0.38 |
+ 0.75 < PRx ≤ + 1.0 (GMT) [8] | 0.93 (0.88–0.98) | 0.02 | 0.91 (0.84–0.97) | 0.01 |